<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/62C544E8-A6D5-4B0C-9773-7A30B21F968D"><gtr:id>62C544E8-A6D5-4B0C-9773-7A30B21F968D</gtr:id><gtr:name>University of Padua</gtr:name><gtr:address><gtr:line1>Universita di Padova</gtr:line1><gtr:line4>Padova</gtr:line4><gtr:postCode>35129</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/11E604AE-3915-4673-AEA6-852F7D6BFFD8"><gtr:id>11E604AE-3915-4673-AEA6-852F7D6BFFD8</gtr:id><gtr:name>Wellcome Trust</gtr:name><gtr:address><gtr:line1>183 EUSTON ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1  2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FDA3FC4C-8E75-4C67-9DA6-3482A4A94186"><gtr:id>FDA3FC4C-8E75-4C67-9DA6-3482A4A94186</gtr:id><gtr:name>Drugs for Neglected Diseases initiative (DNDi)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E9066440-7923-4DA5-9C32-D4A1055C7DA6"><gtr:id>E9066440-7923-4DA5-9C32-D4A1055C7DA6</gtr:id><gtr:name>Cipla</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC20619C-24CC-4562-8F2A-B1C34FB19874"><gtr:id>FC20619C-24CC-4562-8F2A-B1C34FB19874</gtr:id><gtr:name>University Medical Centre Nijmegen</gtr:name><gtr:address><gtr:line1>Uinversity Medical Centre Nijmegen</gtr:line1><gtr:line2>PO Box 9101</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/62C544E8-A6D5-4B0C-9773-7A30B21F968D"><gtr:id>62C544E8-A6D5-4B0C-9773-7A30B21F968D</gtr:id><gtr:name>University of Padua</gtr:name><gtr:address><gtr:line1>Universita di Padova</gtr:line1><gtr:line4>Padova</gtr:line4><gtr:postCode>35129</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/11E604AE-3915-4673-AEA6-852F7D6BFFD8"><gtr:id>11E604AE-3915-4673-AEA6-852F7D6BFFD8</gtr:id><gtr:name>Wellcome Trust</gtr:name><gtr:address><gtr:line1>183 EUSTON ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1  2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FDA3FC4C-8E75-4C67-9DA6-3482A4A94186"><gtr:id>FDA3FC4C-8E75-4C67-9DA6-3482A4A94186</gtr:id><gtr:name>Drugs for Neglected Diseases initiative (DNDi)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E9066440-7923-4DA5-9C32-D4A1055C7DA6"><gtr:id>E9066440-7923-4DA5-9C32-D4A1055C7DA6</gtr:id><gtr:name>Cipla</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC20619C-24CC-4562-8F2A-B1C34FB19874"><gtr:id>FC20619C-24CC-4562-8F2A-B1C34FB19874</gtr:id><gtr:name>University Medical Centre Nijmegen</gtr:name><gtr:address><gtr:line1>Uinversity Medical Centre Nijmegen</gtr:line1><gtr:line2>PO Box 9101</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4CFEE661-9281-4E12-B253-109123EF97A4"><gtr:id>4CFEE661-9281-4E12-B253-109123EF97A4</gtr:id><gtr:firstName>Ann</gtr:firstName><gtr:otherNames>Sarah</gtr:otherNames><gtr:surname>Walker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/58B69503-B9E3-43E3-AEB2-82D521E4C95E"><gtr:id>58B69503-B9E3-43E3-AEB2-82D521E4C95E</gtr:id><gtr:firstName>Diana</gtr:firstName><gtr:surname>Gibb</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U122886353"><gtr:id>57051FA7-7F78-44E0-AB60-DF079A648704</gtr:id><gtr:title>Paediatric programme - HIV and other diseases of poverty</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U122886353</gtr:grantReference><gtr:abstractText>Our studies aim to improve management of children with severe illnesses of poverty (predominantly HIV, Malaria, bacterial infections, TB) worldwide. We have 20 years experience of HIV in children, inintially in Europe, now mainly in Africa. In Europe, prevention of mother-to-child HIV transmission has reduced new infections in babies, but many children are now entering adolescence. Our research is finding out the best medicines with the fewest longterm side-effects, as children have to take treatment for life. In UK, we are starting a new study (AALPHI) to find out how HIV and its treatment affects young people entering adulthood. |Rollout of HIV treatment in Africa is increasing, bringing many questions about how best to do this in countries with few trained staff or health infrastructure. HIV-infected children have many other problems including malnutrition, tuberculosis, bacterial infections, malaria; without treatment, ~50% die before their second birhtday. We are undertaking large studies with colleagues in south/east African countries aimed at providing ways to enable more children to access HIV treatment. |Throughout Africa, death from malaria and other severe infections is unacceptably high, most occurring &amp;lt;24 hours after admission to hospital. Little attention has been paid to resuscitation with fluids. We are working with colleagues in Kenya to find out the best way to resuscitate these very sick children, particularly with malaria.</gtr:abstractText><gtr:technicalSummary>The CTU paediatric programme of trials and cohorts of childhood diseases of poverty - HIV, malaria, tuberculosis and sepsis - aims to generate evidence to inform policy and practice in both well-resourced and resource-limited countries worldwide, particularly Africa. |The PENTA (Paediatric European Network for treatment of AIDS, www.pentatrials.org) program (funding EU 1990-2015) undertakes cohorts and trials in ~15 countries in Europe, South America, Asia(Thailand) and Africa (Uganda) addressing questions on HIV-infection in children which cannot be extrapolated or assumed from adult studies. New trials aimed at older children/adolescents focus on strategies to maximise efficacy and adherence to antiretroviral therapy (ART) while minimising longterm toxicity (PENTA 16, 18 &amp;amp; 20 trials). Two trials recently completed: (1)PENTA 11, a trial of CD4-guided treatment interruptions (AIDS 2010) has 5 year follow-up ongoing; (2)PENPACT1: a 5-year trial of what treatment to start and when to switch will be presented at World AIDS 2010. |Individual patient meta-analyses of European cohort data address multiple questions, including informing trial design, facilitating recruitment and longterm follow-up during/after trials, comparisons between adults and children and pharmcovigilance information for the EMEA. The Childrens HIV Paediatric Study (CHIPS, a UK/Irish paediatric HIV cohort, www.chipscohort.org, DOH funding 1990-), contributes to the above and also provides annual feedback to inform national paedaitric HIV services. Recently (2012) a new cohort study of HIV-infected adolescents and HIV-negative controls has started recruitment. It will evaluate long-term health outcomes in these two groups, with a particular focus on neurodevelopment, quality of life and growth. |In Africa, large ongoing trials in Uganda, Zambia, Zimbabwe and South Africa (total ~2,500 children) are addressing multiple management questions including: when to start ART in children; when and whether ART can be stopped after early treatment; how to monitor children on ART; simplification of ART using fixed dose combination baby pills and once-daily dosing; whether cotrimoxaozole prophylaixs can be stopped in children on ART. Several trials have 2 or more randomisations (in factorial design), have multiple substudies (e.g. pharmacokinetics, adherence, co-morbidities tuberculosis, sepsis, malnutirition) and include additional social science and economic components. A new trial addressing ways to reduce early mortality in HIV-infected adults and children is planned. |In collaboration with Wellcome Trust centre, Kilifi, Kenya, FEAST (www.Feast.org, 2009-2011) is a large (3,600) pragmatic trial evaluating fluid resuscitation strategies in sick children in Uganda, Tansania and Kenya, predominantly due to malaria and sepsis. CTU plays a key role in design, analysis and mentoring. A new trial evaluating transfusion, antibiotic and prophylaxis strategies in sick anaemic children coming into hospital is in the planning stages (TRACT trial).</gtr:technicalSummary><gtr:fund><gtr:end>2013-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>15963070</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Paediatrics</gtr:department><gtr:description>Imperial College, London</gtr:description><gtr:id>0883D5AA-4540-42EC-9E4C-53F65F1A4F9D</gtr:id><gtr:impact>The FEAST trial paper in NEJM, follow up papers ongoing. BMJ paper of the year 2012.</gtr:impact><gtr:outcomeId>sKSRAUJ1bMm-1</gtr:outcomeId><gtr:partnerContribution>Collaborators of the trial monitoring network in East Africa. The FEAST trial monitors also monitored the VITA trials in Tanzania.
Dr Hermione Lyall was a Trial Steering Committee (TSC) member of the ARROW trial and is chair of the EndPoint Review Committe for CHAPAS 3. Dr Gareth Tudor-Williams is chair of the EndPoint Review Committee for ARROW. Clinical trial site for REALITY.</gtr:partnerContribution><gtr:piContribution>Scientific leadership designing the TRACT (awarded &amp;pound;3,497,084 not yet started) and FEAST trials in collaboration with Professor Kath Maitland (Imperial College and KEMRI Wellcome Trust). Analysis and writing up of the FEAST trial; oversight of trial management and mentoring the trial team in Kilifi.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellcome Trust</gtr:collaboratingOrganisation><gtr:country>Kenya, Republic of</gtr:country><gtr:department>KEMRI-Wellcome Trust Research Programme</gtr:department><gtr:description>Kemri Wellcome Trust, Kilifi Kenya</gtr:description><gtr:id>66ED6247-914A-459D-B951-38FA9119A9CB</gtr:id><gtr:impact>The FEAST trial paper in NEJM, follow up papers ongoing. BMJ paper of the year 2012.</gtr:impact><gtr:outcomeId>LKeAsFc6Eu3-1</gtr:outcomeId><gtr:partnerContribution>the CTU lead network of trial monitoring in East Africa. The FEAST trial monitors also monitored the VITA trials in Tanzania. Trial sites for REALITY Trial</gtr:partnerContribution><gtr:piContribution>Scientific leadership designing the TRACT and FEAST trials in collaboration with Professor Kath Maitland (Imperial College and KEMRI Wellcome Trust). Analysis and writing up of the FEAST trial; oversight of trial management and mentoring the trial team in Kilifi. Chair of Trial Steering Committe of Cotrimoxizole trial for Jay Berkley.</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>National Institute of Health</gtr:description><gtr:id>5BAF1827-A86B-40CE-911C-6F64FFCBFC7B</gtr:id><gtr:impact>Papers from the CHER trial and PENPACT-1 trial, papers from HPPMCS.</gtr:impact><gtr:outcomeId>aHEqC2f25VC-1</gtr:outcomeId><gtr:partnerContribution>We have collaborated with NIH who funded the CHER trial in South Africa through a CIPRA grant.

NIH have contributed funding and collaboration on the PENPACT-1 trial</gtr:partnerContribution><gtr:piContribution>Provide scientific input in to all aspects of desgin, analysis and write up of the CHER trial (Prof Diana Gibb and Prof Abdul Babiker).

With Prof Lynne Mofenson at NIAID we have worked on PENPACT-1 trial and cohort collaborations (HPPMCS).</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of York</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>York Health Economics Consortium (YHEC)</gtr:department><gtr:description>University of York</gtr:description><gtr:id>DBB37032-4351-4791-A8FA-9497F7B624D0</gtr:id><gtr:impact>Paul Revill has led a cost effectiveness analysis of the ARROW data which is in the process of being published, he also leads a team of African economists (including capacity building working on the DFID funded Lablite project).</gtr:impact><gtr:outcomeId>MkfMiiwHNiy-1</gtr:outcomeId><gtr:partnerContribution>The Health Economics team led by Professor Mark Sculpher collaborate on cost effectiveness analyses linked to clincal trials and economic evaluations including equity and modelling for medical decision makers in health</gtr:partnerContribution><gtr:piContribution>MRC CTU coordinates programmes of trials and implementation projects.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Drugs for Neglected Diseases initiative (DNDi)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Paediatric Programme</gtr:department><gtr:description>DNDI (Drugs for Neglected Diseases Initiative)</gtr:description><gtr:id>C1D3541C-9F2B-49F1-94FA-1112463BD4CC</gtr:id><gtr:impact>Prof A Kekitiinwa, Principal Investigator at one of the Uganda sites for CHAPAS 2, was an invited speaker in a DNDI sponsored satelitte meeting on formulations for children at the AIDS 2012 Conference.</gtr:impact><gtr:outcomeId>VY4pfjL8PBp-1</gtr:outcomeId><gtr:partnerContribution>DNDI has funded the second cohort of the CHAPAS 2 trial and discussions are underway with Dr Marc Lallemant (Head of Paediatric HIV Programme) for further collaboration.</gtr:partnerContribution><gtr:piContribution>MRC CTU co-ordinates the CHAPAS-2 trial.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Radboud University Nijmegen Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Radboud University Nijmegen Medical Centre, the Netherlands</gtr:description><gtr:id>E7F1C7EA-AC17-46F3-99E6-8DD6D38B219B</gtr:id><gtr:impact>Radbound University has been involved in the analysis and writing up of the pharmacokinetics data from ARROW, PENTA 18 and the CHAPAS trials which has resulted in presentations at international conferences, peer review publications, FDA and EMA approval of drugs and Clinton Foundation and UNITAID dissemination in Africa.</gtr:impact><gtr:outcomeId>eiDfjRLy7oE-1</gtr:outcomeId><gtr:partnerContribution>Long standing nesting of key pharmacokinetic studies within larger trial programmes. Contributed to several PhD studentships (all Dutch), PK data resulted in licensing of new appropriate antiretroviral formulations for children in resource limited settings.</gtr:partnerContribution><gtr:piContribution>The research team at the MRC co-ordinates the ARROW, CHAPAS-1,2,3 and PENTA trials and provides scientific input and analysis of EDCTP funded VITA 1 and 2 trials.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Padova</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>EPPICC (European Paediatric and Pregnancy HIV Cohort Collaboration)</gtr:description><gtr:id>D7A436B2-6F06-4676-9C2E-931AC0BA09A7</gtr:id><gtr:impact>Goetghebuer T, Haelterman E, Le Chenadec J, Dollfus C, Gibb D, Judd A, et al. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS 2009,23:597-604.

European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC). Fosamprenavir use in children in the European Union. A report to the European Medicines Agency (EMA), August 2009 (and repeated August 2010). London: MRC Clinical Trials Unit.

European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC). Early antiretroviral therapy in HIV-1 infected infants in Europe, 1996-2008: treatment response and duration of first line regimens. AIDS. 2011;25:2279-2287.</gtr:impact><gtr:outcomeId>mnfF9mvvWAa-1</gtr:outcomeId><gtr:partnerContribution>We are leading a new collaborative project (EPPICC infants) for this network, and the network has provided us with data to make the project feasible. The network also contributes epidemiological and clinical expertise to the project.</gtr:partnerContribution><gtr:piContribution>We co-lead this network of paediatric observational HIV cohorts along with the Institute for Child Health. We have co-written the strategic plan for this network for the next 5 year period and have contributed to the EuroCoord bid which has secured funding for this network for the next 5 years.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cape Town</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:department>Division of Clinical Pharmacology</gtr:department><gtr:description>University of Cape Town</gtr:description><gtr:id>BE014FCD-6744-46B5-A5D4-890700CE62EE</gtr:id><gtr:impact>Analyses of CHAPAS 3 data are currently in progress</gtr:impact><gtr:outcomeId>MccLbSszTQf-1</gtr:outcomeId><gtr:partnerContribution>Dr Helen McIlleron's team designed, coordinate and analyse pharmacokinetic studies in collaboration with Prof David Burger from Nimejgen. 

Collaboration between MRC CTU at UCL, Harvard University and University of Cape Town to be Data Center for CIPHER global cohort collaboration. Clinical site for PENTA 17 (SMILE) and PENTA 20 (ODYSSEY) clinical trials</gtr:partnerContribution><gtr:piContribution>MRC CTU coordinates the CHAPAS 3, PENTA 17 (SMILE) and PENTA 20 (ODYSSEY) clinical trials.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cipla</gtr:collaboratingOrganisation><gtr:country>India, Republic of</gtr:country><gtr:description>Cipla</gtr:description><gtr:id>A95AD5E9-E09F-441B-BDD9-7F476C1F8247</gtr:id><gtr:impact>The results of the CHAPAS 1 trial were used towards the licensing by the FDA of Triomune Baby/Junior Fixed Dose Formulations for children. CHAPAS 2 &amp;amp; 3 trials will provide data for licensing these important formulations for children in Africa.</gtr:impact><gtr:outcomeId>eYVJXsYu4WD-1</gtr:outcomeId><gtr:partnerContribution>Cipla have donated antiretroviral drugs for the children participating in these trials.</gtr:partnerContribution><gtr:piContribution>MRC CTU coordinated the CHAPAS 1,2,3 trials.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>PENTA newsletters for participants</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>6039CA1E-B2A0-4581-AE70-C90F7FFF8157</gtr:id><gtr:impact>regular newsletters update about ongoing trials and results

Appreciated by participants</gtr:impact><gtr:outcomeId>eWvccfYstuA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Policy brief: Challenging fluid resuscitation for critically sick children in Africa (FEAST)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5AEDDFD7-2E19-46D7-9B2C-27222EB4190F</gtr:id><gtr:impact>The policy brief, summarising the results of the FEAST trial, has been distributed to healthworkers and policymakers from ten African countries, and international agencies such as the World Health Organisation and Medicins Sans Frontiers.

Further copies of the policy brief have been requested (and sent) for distribution to Zambia Paediatric Association. The implications of FEAST have been discussed by the paediatric associations of several African countries.</gtr:impact><gtr:outcomeId>NadNv8S6WJf</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>FEAST engagement with media over BMJ paper</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>85F5C83D-1970-47BC-B49F-48A76E344CEC</gtr:id><gtr:impact>The story was covered by the Today Programme, BBC World Service, BBC News website, Guardian.

The World Health Organisation responded, saying they would release updated guidelines by the end of the year.</gtr:impact><gtr:outcomeId>5457a637c67962.46297055</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:url>http://www.ctu.mrc.ac.uk/news/2014/current_septic_shock_treatment_guidelines_are_putting_childrens_lives_at_risk_140114</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>FEAST information pack</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E37FAAFD-6F0F-4B54-BBA6-FA98C10C2F1C</gtr:id><gtr:impact>The information pack has been distributed to international policymakers including the World Health Organisation, international NGOs such as Medicins Sans Frontiers, and representatives of paediatric associations from ten African countries.

The implications of FEAST have been discussed by the paediatric associations of several African countries.
A small group is being convened to work on revising the ETAT and ETAT+ guidelines</gtr:impact><gtr:outcomeId>teWhGAH3fBC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ARROW Cotrimoxazole film</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>32D427F0-49B3-4ADE-87C0-5E599E38767F</gtr:id><gtr:impact>Film about the ARROW cotrimoxazole results released on YouTube.

161 views so far from the YouTube website. Unsure how many views from the MRC CTU website.</gtr:impact><gtr:outcomeId>5457a88bbd41f3.58382695</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.youtube.com/watch?v=D1n_We7x8Do</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Aids Treatment Information Centre (ATIC) Newsletter on Development of New Paediatric Antiretroviral Formulations.  CHAPAS-1 was used as a case study</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>8872A244-0012-41D7-9F17-5CD5BF89C679</gtr:id><gtr:impact>A newsletter that was distributed to healthcare providers throughout Uganda

The article was well received in Ugandan audience.</gtr:impact><gtr:outcomeId>J5WB4vTxAcw</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PENTA Website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>07F0B98C-DE4D-4D74-B17A-15D4DBF85D0D</gtr:id><gtr:impact>Includes detials of trials, updated news, publications, guidelines for antiretroviral therapy in children, links to HPPMCS risk calculator for clinicians, links to the CHIVA website,

regular traffic of emails asking questions and indicating appreciation</gtr:impact><gtr:outcomeId>BRNNwApJJ6H</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lablite briefing paper: Access to lab tests</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AA10DE37-9246-4212-A12B-3DD7362DE150</gtr:id><gtr:impact>Policy brief developed based on results of Lablite baseline survey. Currently being distributed.

Too early to say.</gtr:impact><gtr:outcomeId>5457a53dd88843.04992502</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:url>http://www.ctu.mrc.ac.uk/13706/13710/Access_to_lab_testing_at_primary_health_facilities</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CHIVA</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B3BE8DE4-5306-4278-A036-D9F96CF1A77E</gtr:id><gtr:impact>Twice yearly contribution of lay text on the CHIPS study to the CHIVA Newsletter; yearly presentation of key findings from the CHIPS and AALPHI studies at the CHIVA national conference. Updating on results and ongoing PENTA trials

Improved reporting of patients to CHIPS, and general understanding of the CHIPS data and its importance. Recruitment of patients into PENTA trials</gtr:impact><gtr:outcomeId>UiRSqiT5Mbj</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CHAPAS-1 policy briefs</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>8D80D339-E073-4CA5-9AD8-DE50CC0B7EFD</gtr:id><gtr:impact>A policy brief describing the main results of CHAPAS-1 and the advantages of fixed dose combination tablets for children.

The case studies were well received in Zambia and by African audience.</gtr:impact><gtr:outcomeId>K6pd5PJABMf</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit to WHO (FEAST)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>FA9158F2-A03A-4B6B-BEBF-F32F7DB7284D</gtr:id><gtr:impact>WHO awaiting results of trial. They would like to use the results and our expertise to advise of fluid management of the severely ill child

WHO are the key policy maker who advise on guidelines for management of children in LED countries including Africa. FEAST will direct inform policy.</gtr:impact><gtr:outcomeId>qKzonFhsigD</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ARROW Cotrimoxazole policy brief</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>031961D2-72CF-4C54-A4EF-3F231424CA59</gtr:id><gtr:impact>The policybrief was distributed to policymakers in the Ministry of Health in Uganda and Zimbabwe (where the trial took place). It has also been more widely distributed at meetings, and is available on the MRC CTU website.

Feedback from policymakers at the Ministry of Health was very positive about the policy brief.</gtr:impact><gtr:outcomeId>5457a42d64d968.58380047</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:url>http://www.ctu.mrc.ac.uk/12602/13009/children_on_art_in_africa_need_to_continue_cotrimoxazole_prophylaxis</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Communication Strategy for stakeholders (FEAST)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>49083D36-1D0F-43ED-8486-F7EAB44206C6</gtr:id><gtr:impact>Communication Strategy was developed for the main stakeholders - including health professionals, policy makers and public. Primarily designed to raise awareness of the existance and potential impact of the trial. 


Communities and hospitals were anxious to know the outcome of the study when published</gtr:impact><gtr:outcomeId>NvPbAwRxPX9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Anatomy of a clinical trial film</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DE9BE321-A83B-4287-9FDA-E597F268F063</gtr:id><gtr:impact>A film was developed, targeted at healthworkers, explaining the importance of clinical trials, using FEAST as an example. This film has been shown at a conference in South Africa, as well as being made available on YouTube and the MRC CTU website.

The film has had almost 500 views online. Health workers watching the film reported finding the interviews with the trial team before they found out the results, and watching them learn the results, to be very persuasive.</gtr:impact><gtr:outcomeId>ik29TL1i7jc</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://www.youtube.com/watch?v=GdMMuURsZQg&amp;list=UUxUK9Zn4Es5SxMbAYeTSO2g</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lablite briefing paper: Children's access to ART</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>30A43955-E284-4C89-B4EC-CF60FED9D198</gtr:id><gtr:impact>Briefing paper developed based on results of Lablite baseline survey. Currently being distributed.

Currently being distributed.</gtr:impact><gtr:outcomeId>5457a5a285d9f9.76773072</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ctu.mrc.ac.uk/13706/13710/Childrens_access_to_art</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>talks/workshops to adolescents with HIV infection about research including understanding of clinical trials</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DBFB24E2-5675-4B5A-8F46-B1FC6C9E3C42</gtr:id><gtr:impact>eg workshop of &amp;gt;100 young people with HIV;

resulting in more active participation of young people with HIV in thinking about reserach</gtr:impact><gtr:outcomeId>sEi9qk3Vowd</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CHAPAS-1 participants meetings</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>4DA5CAFE-4459-46C1-AA3C-6CDD53652D0F</gtr:id><gtr:impact>The CHAPAS-1 centre held a participants day/celebration after the final Trial Steering Committee to feedback the results of the trial to participants. Presentations were done by trial staff.

Participants were very appreciative of being told results early in the dissemination process. Throughout the trial, regular meetings with participants enabled researchers to become aware of concerns and issues before these developed into major problems.</gtr:impact><gtr:outcomeId>nWyTYdvMEXf</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CHER long-term results press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3D57B3F6-0E94-4E7D-AF41-CF5E2FD96184</gtr:id><gtr:impact>A press release was issued regarding the long-term results of CHER.

This was covered by an article on the AFP News wire.</gtr:impact><gtr:outcomeId>g97RbVEfYrY</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lablite briefing paper 1: prioritising improving laboratory monitoring or scaling up ART</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>71D967B6-588D-4187-8C9D-C8366633E173</gtr:id><gtr:impact>Briefing paper developed based on results of modelling study.

.</gtr:impact><gtr:outcomeId>5457a4af90d578.91826571</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:url>http://www.ctu.mrc.ac.uk/13706/13710/prioritising_increasing_access_to_art_or_improving_monitoring_of_patients_already_on_art</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>London Specialised Commissioning Group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6A08FC19-4E39-4DFD-BBC8-31B7221BFE6A</gtr:id><gtr:impact>Annual production of a newsletter (annual report) and slide set which presents CHIPS data in lay language. Presentation of data at twice yearly London HIV Consortium meetings

CHIPS data are now used as the basis for commissioning paediatric HIV services across England, and are being developed to measure quality of services within new designation schemes.</gtr:impact><gtr:outcomeId>NUaMBtmzJVX</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Fluid Resuscitation Meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FC557969-DAEE-4F3F-96D1-D4FCE7E89C16</gtr:id><gtr:impact>Working with Kenya Paediatric Association we convened a workshop with representations from the paediatric associations of ten sub-Saharan African countries. This meeting looked at the evidence on fluid resuscitation of children, including that from the FEAST trial, and discussed the implications for policy and practice.

It was agreed that a small group would work on revising the ETAT and ETAT+ guidelines incorporating the evidence from FEAST. Participants in the meeting would also raise the issue with their national paediatric associations, with the aim of updating national policy.</gtr:impact><gtr:outcomeId>Mp7m37UixhS</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>Ireland, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Development Corporation Ireland (DCI)</gtr:department><gtr:description>The Cost Effectiveness of Antiretroviral Therapy in the CHAPAS Trials/Development Corporation Ireland</gtr:description><gtr:fundingOrg>Government of Ireland</gtr:fundingOrg><gtr:id>881C89F2-5561-41E8-BA74-9807B2866636</gtr:id><gtr:outcomeId>ga894CHU9qH0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>319534</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>Children with HIV in Africa - Pharmacokinetics and Adherence of Simple Antiretroviral Regimens (CHAPAS-1 trial)</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>B611BC11-17B5-4493-9089-BE7D06689155</gtr:id><gtr:outcomeId>ojeCezA8bVT0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Medical Research Foundation</gtr:department><gtr:description>Development of Antiretroviral Therapy in Africa (Medical Research Fund - Alexander Fleming Dissemintion Scheme)</gtr:description><gtr:end>2010-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>4A6F6BE9-CDC6-4824-A64A-F0DCD2A53D61</gtr:id><gtr:outcomeId>a577Pz7ecfH0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>52800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DART Substudy: Follow-up of infants born to HIV infected women in the DART study/Gilead Sciences</gtr:description><gtr:end>2009-12-02</gtr:end><gtr:fundingOrg>Gilead</gtr:fundingOrg><gtr:id>0739A7E4-9775-468F-9CAC-2E97313F4038</gtr:id><gtr:outcomeId>kz538qPozvn0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2006-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2144054</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A multi-centre randomised controlled trial of volume expansion in children with severe malaria (FEAST)</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>2B9C91F7-5179-4A0E-9E00-E5E41EFAA382</gtr:id><gtr:outcomeId>BNZFTtKS23z0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4617034</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>CHAPAS 3: Expanding the Availability of Fixed Dose Combination Antiretroviral Formulations for First-line Treatment of HIV-infected Children - the Children with HIV in Africa Pharmacokinetics and Acceptability/Adherence of Simple Antiretroviral Regimens</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>DABA6492-345A-4B9E-A432-2A556F2072A7</gtr:id><gtr:outcomeId>58c81606b84125.98950577</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>531261</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PENTA 16 Trial: Short-Cycle Therapy (SCT) (5 days on/2 days off) in young people with chronic HIV-infection/Health Technology Assessment</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>4F6D702C-CB16-4575-8F20-0694C8637273</gtr:id><gtr:outcomeId>JahRotKVm950</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>36637</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Audit of Tenofovir in HIV infected children in UK/Gilead</gtr:description><gtr:end>2009-09-02</gtr:end><gtr:fundingOrg>Gilead</gtr:fundingOrg><gtr:id>80EAC010-6546-4A1E-B288-C3866A3F6EC0</gtr:id><gtr:outcomeId>sjYZnLA3M6p0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2006-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60773</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Health Technology Assessment Programme (HTA)</gtr:department><gtr:description>Does short cycle antiretroviral therapy impact on inflammation, immune activation, thrombogenesis and CD4 cell dynamics?</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>11/136/108</gtr:fundingRef><gtr:id>1E89BEB9-CB91-4CE0-8278-06962B0089C5</gtr:id><gtr:outcomeId>dHbYxfgCuXs</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>371694</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Fellowship Julia Kenny (CHAPAS 3 Trial &amp;amp; Substudies)</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>CD257DD6-CD25-4154-83B6-BF96E0B3E979</gtr:id><gtr:outcomeId>Cq7d9Nu3bJS</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3217996</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A randomized controlled trial of shorter course treatment for uncomplicated minimal childhood tuberculosis (SHINE)</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>E994FABF-10DF-4079-AE7B-719342FCCF6E</gtr:id><gtr:outcomeId>nkQTM2TMiLg</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>850000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Monument Trust</gtr:department><gtr:description>Adolescents and Adults Living with Perinatal HIV cohort (AALPHI)/ Monument Trust (Sainsbury Family)</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>The Sainsbury Family Charitable Trusts</gtr:fundingOrg><gtr:id>5C86ED43-DC70-48F2-B292-55A5D72EAB5D</gtr:id><gtr:outcomeId>K4GH5bCyJqw0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>314606</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Fellowship Helen Payne (Immunology substudies in CHER Trial)</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>EE1A87C4-1436-4596-80CF-FC5493CEB75B</gtr:id><gtr:outcomeId>QwUfDbB41pQ</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Medical Research Foundation</gtr:department><gtr:description>Alexander Flemming Dissemination Grant (FEAST)</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>CBD9AECA-240C-40E9-8C55-07A79FDB6BF1</gtr:id><gtr:outcomeId>NmL67YX9qBt0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>67648</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Support for UK clinical centres enrolling in PENTA trials</gtr:description><gtr:end>2009-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>CE5BFE49-51EF-4AFC-BE04-B217CB8FEEEF</gtr:id><gtr:outcomeId>f11nMTBkCT90</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>44577</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Network of Excellence: Task Force in Europe for Drug Development for the Young, (TEDDY) 4.4m euros across 18 participants</gtr:description><gtr:end>2010-06-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>4F61391D-5264-41E3-9B91-B9C25C1FB133</gtr:id><gtr:outcomeId>n7odkM7tdSD0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2005-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1896304</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Department for International Development (DfID)</gtr:department><gtr:description>Optimising Clinical Care, Treatment Strategies and Use of laboratories for ART Roll Out in Africa: The Lab-Lite Project</gtr:description><gtr:end>2015-05-02</gtr:end><gtr:fundingOrg>Government of the UK</gtr:fundingOrg><gtr:id>BBA0EF7E-B15D-48C1-8C3F-3CF71C4CA8AA</gtr:id><gtr:outcomeId>KPPLL9JarTb0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1556696</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Collaboration Agreement - PENTA/EPPICC</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>PENTA Foundation</gtr:fundingOrg><gtr:id>CA20CBA4-8174-45B6-9DD7-25CECD1E3604</gtr:id><gtr:outcomeId>VEzbSde75zN</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>683863</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>Children with HIV in Africa Pharmacokinetics and Acceptability/Adherence of Simple Antiretroviral Regimens CHAPAS-3 Trial/EDCTP</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>78498702-B9F3-4F79-9806-9F2EF236051F</gtr:id><gtr:outcomeId>MUQeVTA3mYb0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>129636</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Support for enrolment of additional children into joint PENTA/PACTG Penpact 1 Trial/National Institute of Child Health and Human Development, USA</gtr:description><gtr:end>2009-01-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>95F706CB-FAF4-4A02-BB9F-236F9880BFAA</gtr:id><gtr:outcomeId>iigvo3RpMSH0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2003-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Network Treatment AIDS Laboratory Network (PENTA LABNET)</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>92C7B68E-227C-4929-B493-3762C61392F4</gtr:id><gtr:outcomeId>Ar8UTC3tKoe0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>788800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Department for International Development (DfID)</gtr:department><gtr:description>Young Lives: the Social Contexts of Paediatric Anti-Retroviral Therapy. A DFID Social Science programme in Uganda and Zimbabwe</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Government of the UK</gtr:fundingOrg><gtr:id>7F849FD9-AF8A-4791-A78D-84E0CFB1A982</gtr:id><gtr:outcomeId>pgWmpHdMoEt0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3986746</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Reduction of Early mortaLITY in HIV-infected African adults and children starting antiretroviral therapy: REALITY trial</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>C1F18379-A8AA-4C50-858B-DB0019A02B44</gtr:id><gtr:outcomeId>NyLSsPjZd1q1</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>Networking grant: Identifying the common learning needs of investigators working in poverty-related diseases in African settings, areas of project and data/The European &amp;amp; Developing Countries Clinical Trials Partnership</gtr:description><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>68C78E33-5A3E-41D2-A583-67B726CFF99F</gtr:id><gtr:outcomeId>bM4PfJRDWGe0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>780000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Collaborative HIV Paediatric Study (CHIPS)/Department of Health</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>NHS England</gtr:fundingOrg><gtr:id>E508B88C-D68B-499E-9FA0-3D526EEA8A52</gtr:id><gtr:outcomeId>NMP6s6mw7xy0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>Ireland, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Development Corporation Ireland (DCI)</gtr:department><gtr:description>The Cost Effectiveness of Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected African children in the CHAP trial/Development Corporation Ireland</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>Government of Ireland</gtr:fundingOrg><gtr:id>1FE0C293-7BD5-417C-B80A-24CDC1E6C0C3</gtr:id><gtr:outcomeId>jjCykbW3s760</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>479000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Department for International Development (DfID)</gtr:department><gtr:description>Trial of Cotrimoxazole prophylaxis in HIV Infected Children in Zambia (CHAP) - including extension for microbiology and after-trial follow-up</gtr:description><gtr:fundingOrg>Government of the UK</gtr:fundingOrg><gtr:id>CEFAD7D7-C748-41CC-8B70-737A06669F2D</gtr:id><gtr:outcomeId>ThzMBUrwAkJ0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>Networking Grant for Clinical Pharmacology in Sub Saharan Africa/The European &amp;amp; Developing Countries Clinical Trials Partnership</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>A8D7A721-6D1E-4FE9-A7CC-96D9C55D3018</gtr:id><gtr:outcomeId>ZZuWQWJRfLv0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>463158</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Paediatric European Network Treatment AIDS and European Collaborative Study on HIV infected pregnant women and their children: renewal of the PENTA Concerted Action</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>E493282F-4482-4516-BC34-7F91913CC049</gtr:id><gtr:outcomeId>FjqNCE4xuNz0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>205907</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Training Fellowship - Felicity Fitzgerald</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7757834C-04B3-4AD7-B41A-D4561E5DB374</gtr:id><gtr:outcomeId>T6qqdR6LjgQ</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO expert consultation for global recommendations on cotrimoxazole prophylaxis for HIV infection in adults and children, Geneva</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>1A8B9983-E740-4555-9157-9F3E8D9C07A6</gtr:id><gtr:impact>accepted as the evidence base for cotrimoxazole prophylaxis in adults and children with HIV infection in resource-limited settings worldwide. incorporated into most national guidelines</gtr:impact><gtr:outcomeId>iMMtuuVGjhT</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in PENTA guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection</gtr:guidelineTitle><gtr:id>ABEC920E-AE6C-4F22-95DD-00E33F55B0DD</gtr:id><gtr:impact>CHIPS data contributed evidence to the section describing testing strategies for children newly arriving within the EU and presenting to health services</gtr:impact><gtr:outcomeId>jRfg5MbmPAs</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.pentatrials.org/guide09.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO guidelines 2013 - health economics and modelling</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:guidelineTitle>WHO consolidated ART guidelines 2013</gtr:guidelineTitle><gtr:id>57D60216-C686-4008-AFF6-386BE790F8FA</gtr:id><gtr:outcomeId>5460ee8475b448.04253229</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://apps.who.int/iris/bitstream/10665/93524/1/WHO_HIV_2013.56_eng.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO guidelines 2013 - health economics and modelling</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:guidelineTitle>WHO consolidated ART guidelines</gtr:guidelineTitle><gtr:id>52B9A124-36F7-44E4-8932-55B7D092437F</gtr:id><gtr:outcomeId>5460edf641dd16.93898926</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://apps.who.int/iris/bitstream/10665/91043/1/WHO_HIV_2013.60_eng.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Membership of PENTA Guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>09ED0749-4E76-46B6-9AF8-C74F6E0D685B</gtr:id><gtr:impact>referred to by practitioners and national paedaitric guideline bodies worldwide</gtr:impact><gtr:outcomeId>o54JbHsKmaq</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Generating evidence for when to start treatment for HIV-infected children</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Antiretroviral Therapy of HIV Infection in infants and Children in Resource-Limited Setttings: Towards Universal Access. Recommendations for a public health approach.</gtr:guidelineTitle><gtr:id>55D5DF1F-74C3-46AD-AEB3-6E181CBE978A</gtr:id><gtr:impact>Formed the basis of when to start ART in guidelines in US, WHO, Europe and then National guidelines.

CHER trial results (2007) informed WHO 2008 guidelines on early treatment of infants. results of HPPMCS cohort collaboration informed start treatment guidelines for children after infancy</gtr:impact><gtr:outcomeId>iwXDrMhddbg</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.who.int/hiv/pub/guidelines/WHOpaediatric.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Antiretroviral Therapy of HIV Infection in infants and Children in Resource-Limited Setttings: Towards Universal Access. Recommendations for a public health approach</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>2D743B41-47D2-4900-9CD7-995EEE56883C</gtr:id><gtr:outcomeId>JHhA4jb3Pj3</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influence on WHO ART guidelines 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach</gtr:guidelineTitle><gtr:id>41AF0511-5736-4358-B1D3-5B6EAC8B815E</gtr:id><gtr:outcomeId>YrXzo9aE6TW</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>East Africa Guidelines Panel Recommendations</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:guidelineTitle>Draft recommendations for management of children with severe febrile illness and impaired circulation without signs of severely impaired circulation</gtr:guidelineTitle><gtr:id>C780425D-C830-4185-89C5-936740E7B20D</gtr:id><gtr:outcomeId>Vc4Zmn294ZL</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO Expert advisory group on formulations of antiretroviral drugs for children</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>07A78C5D-1EA9-4681-A8DB-3E0F8077EC8F</gtr:id><gtr:impact>Development of weightband-based dosing tables of antiretroviral drugs, including fixed dose combination drugs for HIV-infected children in resource-limited countries. Used to approach generic companies to make these products and widely used in resource-limited settings. We have provided much of the evidence on which these recommendations are based from pharmacokinetic and other studies</gtr:impact><gtr:outcomeId>cLATT3Hr7hQ</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO guidelines - health economics and modelling</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:guidelineTitle>WHO consolidated guidelines 2013</gtr:guidelineTitle><gtr:id>90416E61-13F4-4AC2-96E5-73414306079C</gtr:id><gtr:outcomeId>5460ed829aebc8.16787055</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://apps.who.int/iris/bitstream/10665/93523/1/WHO_HIV_2013.61_eng.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Core Member of WHO consolidated ARV Guidelines 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>B51883D3-0C97-4FCE-B254-086F981A9C90</gtr:id><gtr:outcomeId>ofzWjpnmBwv</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>DART Trial Film</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>36DE7550-DFAC-43BB-AF41-4ADD974B0813</gtr:id><gtr:impact>Provides evidence that toxcicity monitoring is not required for ARV's in WHO 2010 ARV Guidelines.</gtr:impact><gtr:outcomeId>pzyasTyPWA4</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MSF shock algorithms</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Management of circulatory failure in normally nourished children</gtr:guidelineTitle><gtr:id>43F705AE-9240-4B23-850A-B7C7D63B0AD4</gtr:id><gtr:outcomeId>d3r7F7n7Gr8</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO 2006, 2007, 2008, 2010 World Health Organisation Guidelines Committee for Paedaitric Antiretroviral therapy</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>34A0AC2A-7F8E-45BE-8D07-895792BDF837</gtr:id><gtr:impact>WHO guidelines set the standard for HIV treatment in resource-limited settings</gtr:impact><gtr:outcomeId>EozauBGdkpp</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in US guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. August 16, 2010. Department of Health and Human Services, USA.</gtr:guidelineTitle><gtr:id>40D72CC1-9ACC-43BB-9A13-643EB76218EA</gtr:id><gtr:impact>CHIPS data contributed epidemiological data to assess the general nature of problems in clinical management of HIV in paediatrics, as well as specifically contributing evidence to inform guidance on the use of tenofovir in paediatrics; 
PENTA trials have contributed to evidence for firstline therapy;cohort collaborations including CHIPS and PENTA data form the mainstay of when to start treatment according to age-related CD4 counts and percentages for US guidelines, as well as PENTA and WHO guidelines.</gtr:impact><gtr:outcomeId>GGM3yZ1CFKV</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>FEAST Trial Film</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>787C911B-D1DB-4A48-956E-8B7934E86FB5</gtr:id><gtr:impact>Although WHO Guidelines have not yet changed, practice has changed in the centres who participated in the trial and there ahs been widespread international discussion about these results.</gtr:impact><gtr:outcomeId>L49HbtHWkFV</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Paediatric Medicines Expert Advisory Group to the MHRA</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>66ABCA80-F1A8-4A83-8A69-35D769E4A627</gtr:id><gtr:impact>Advises about paediatric medicines for the MHRA</gtr:impact><gtr:outcomeId>H8Vqdw912GG</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of WHO Maternal and Child Health Guideline Development Group</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>D61DB222-7714-48DD-94ED-5EAF04BF7D4D</gtr:id><gtr:outcomeId>pEGGdBGEpiG</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>5 year follow-up is continuing of children enrolled in PENTA 11 - a randomised study to evaluate CD4 driven planned treatment interruptions in children with HIV infection.</gtr:description><gtr:id>8A78DD81-9781-4EBC-852E-7D3D1C46ADA8</gtr:id><gtr:impact>PENTA 11 and the CHER trial have provided randomised data for the possibility of planned treatment interruptions in HIV treatment.</gtr:impact><gtr:outcomeId>cvLeLguTjcM</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>PENTA 11 - TICCH</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://pentatrials.org</gtr:url></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>All young people enrolled in this clinical trial evaluating the role of Short Cycle Therapy (5 days on, 2 days off) in the management of HIV infection will be followed until July 2014. Young people continued to be followed on their randomised treatment, where appropriate, in a 2 year extended follow-up period until July 2016. Results were presented at CROI 2017</gtr:description><gtr:id>45048338-A2D4-419A-BB26-1F312E894515</gtr:id><gtr:impact>Results were presented at CROI 2017. A further trial is planned to look at the possibility of a short course therapy in settings where viral loads are measured annually.</gtr:impact><gtr:outcomeId>TKMwg1M8zQz</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>BREATHER - PENTA 16</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://pentatrials.org</gtr:url><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Efavirenz 600mg tablets scored once on one side and twice on the other side have been developed by CIPLA Ltd to enable dosing using one tablet from childhood through to adulthood. These tablets have been evaluated in the CHAPAS 3 trial using weight band based dosing for pharmacokinetics and their acceptability to children and carers. These tablets are also now being used in the REALITY trial to treat both children and adults.</gtr:description><gtr:id>319FD020-C9C5-4E7B-ACA3-B7552B3181C6</gtr:id><gtr:impact>This product has the potential to greatly simplify ART provision to both adults and children</gtr:impact><gtr:outcomeId>RMvWMtETk8m</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>CHAPAS 3 - Efavirenz double scored tablets</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>ISRCTN69078957</gtr:ukcrnIsctnId><gtr:url>http://www.controlled-trials.com/ISRCTN69078957</gtr:url><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Fixed dose combination scored dispersable tablet, containing Isoniozid 50mg, rifampicin 75mg and pirozinamide 150mg for the intensive phase and an FDC tablet of isoniazid 50mg and rifampicin 75mg for the continuation phase. These are currently being evaluated in a bio equivalent study in healthy volunteers. If bioequivalent these will be used in SHINE.</gtr:description><gtr:id>11EED580-3A36-4A3E-961C-6E312E7C66B0</gtr:id><gtr:impact>Still under development</gtr:impact><gtr:outcomeId>gUwpFtJcfGW</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>SHINE Fixed dose combination TB treatment for children</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Currently being analysed
Kaletra 100/25ml paediatric tablets once daily in the KONCERT (PENTA 18) in process of submission to FDA</gtr:description><gtr:id>4DBCDD7B-1AD3-43F7-999D-853AA0AC2D06</gtr:id><gtr:impact>If lopinavir is shown to be non-inferior when taken once daily rather than twice daily in terms of virological suppression, we expect this will become the standard of care for this drug.</gtr:impact><gtr:outcomeId>ZZbRwqLkGRc</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>PENTA 18 - Once daily Kaletra 100/25ml</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>ISRCTN02452400</gtr:ukcrnIsctnId><gtr:url>http://www.pentatrials.org</gtr:url><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>evaluated early antiretroviral therapy in HIV infected infants in South Africa</gtr:description><gtr:id>EAC267F5-0288-4D8D-A3D4-2EB5AEE839C9</gtr:id><gtr:impact>changed WHO guidance on when to start ART (2010)</gtr:impact><gtr:outcomeId>cZbjGFvFyqb</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>Children with HIV Early Antiretroviral Therapy (CHER)</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Abamune Junior 120/60mg is in the updated WHO 2013 guidelines for children as an urgently needed formulation. This product has been used in the CHAPAS 3 trial in which data on pharmacokinetics, adherance and acceptability has been collected</gtr:description><gtr:id>7566E7E6-618E-41CB-85D1-9F575B2656B8</gtr:id><gtr:impact>This product will simplify dosing in children</gtr:impact><gtr:outcomeId>WYHUShzEJ47</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>CHAPAS 3 ABC/3TC 120/60mg</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>ISRCTN69078957</gtr:ukcrnIsctnId><gtr:url>http://www.controlled-trials.com/ISRCTN69078957</gtr:url><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Fixed Dose Combination Tablet of 3 antiretrovrials (Stavudine, Lamivudine, Nevirapine)</gtr:description><gtr:id>70AB069C-ACF5-4359-9C4F-242C538A9E9D</gtr:id><gtr:impact>Trial results contributed to tentative approval by FDA, which allowed use by Clinton foundation and other treatment programmes in Africa</gtr:impact><gtr:outcomeId>aBKmqHAUWP5</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>CHAPAS 1 Trial - Triomune Baby/Junior</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2007</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Lopinavir/Ritonavir in a novel minitabs sprinkle formulation have been developed by CIPLA Ltd.</gtr:description><gtr:id>BFEBCD7B-4DB7-4C2D-BC24-7663C5514E43</gtr:id><gtr:impact>CHAPAS 2 showed that minitabs were comparable with syrup in terms of pharmacokinetics and were more acceptable than syrups for younger children who are unable to take tablets.</gtr:impact><gtr:outcomeId>SE2WhY3o5Co</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>CHAPAS 2 Kaletra minitabs</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>ISRCTN01946535</gtr:ukcrnIsctnId><gtr:url>http://www.controlled-trials.com/ISRCTN01946535</gtr:url><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>randomised trial of Cotrimoxazole prophylaxis in Zambian children</gtr:description><gtr:id>CF3B4D1A-2D00-402B-89D4-FFE23BF9A165</gtr:id><gtr:impact>changed WHO guidelines on Cotrimoxazole prophylaxis</gtr:impact><gtr:outcomeId>K2vgBPPbtjV</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>Children with HIV antibiotic prophylaxis</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>central repository with web access and virtula database in France for all PENTA samples</gtr:description><gtr:id>F3B4425B-CCDA-4353-A20C-8BA2193B1684</gtr:id><gtr:impact>ensuring rapid use of valuable clinical trial linked samples</gtr:impact><gtr:outcomeId>mCodehMoEd2</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PENTA biobank</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Data collected for the ongoing trials</gtr:description><gtr:id>7AAE2119-DC15-4731-8782-AE533A2A135F</gtr:id><gtr:impact>Data used in meta-analyses and in modelling</gtr:impact><gtr:outcomeId>KzYK1r1RXz6</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PENTA trials  database</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D337B724-7C54-413B-82B2-FC8FE95F7DAC</gtr:id><gtr:title>Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/866755af7895521225054f3a1832244b"><gtr:id>866755af7895521225054f3a1832244b</gtr:id><gtr:otherNames>LePrevost M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>AwRAKU1jufD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77905BD3-C7B3-47E1-B022-C7D0C5DF7315</gtr:id><gtr:title>Monitoring of highly active antiretroviral therapy in HIV infection.</gtr:title><gtr:parentPublicationTitle>Current opinion in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1f348d127ad0dfafe68772dadfbf883"><gtr:id>d1f348d127ad0dfafe68772dadfbf883</gtr:id><gtr:otherNames>Walker AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0951-7375</gtr:issn><gtr:outcomeId>tFD3jQ5D5Da</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D935724-F225-4273-B720-1678F06949B7</gtr:id><gtr:title>Improved growth and anemia in HIV-infected African children taking cotrimoxazole prophylaxis.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3164abe52910f05ccfe8826fc886f6c9"><gtr:id>3164abe52910f05ccfe8826fc886f6c9</gtr:id><gtr:otherNames>Prendergast A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>nc2at5GHE9b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B53383EF-BDEB-4174-B89A-616952A5D62E</gtr:id><gtr:title>Mortality after fluid bolus in African children with severe infection.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86eb93149109bb11bc7f076a9c50c2ab"><gtr:id>86eb93149109bb11bc7f076a9c50c2ab</gtr:id><gtr:otherNames>Maitland K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>jhCpSSCB1Wi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26172AE8-8F25-47EB-B71F-38A17B69A753</gtr:id><gtr:title>Survey of children accessing HIV services in a high prevalence setting: time for adolescents to count?</gtr:title><gtr:parentPublicationTitle>Bulletin of the World Health Organization</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68e4b019db5eecab17dea5e777ae7f8f"><gtr:id>68e4b019db5eecab17dea5e777ae7f8f</gtr:id><gtr:otherNames>Ferrand R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0042-9686</gtr:issn><gtr:outcomeId>bHB8NtyZ25S</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98312409-B871-4F2A-AD62-F6FED7153903</gtr:id><gtr:title>Age-dependent pharmacokinetics of lamivudine in HIV-infected children.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37c0e3a7bdd39380fca79da89a5d31f7"><gtr:id>37c0e3a7bdd39380fca79da89a5d31f7</gtr:id><gtr:otherNames>Burger DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>Q3JQmi4fUQW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E149C1F9-60D3-48AD-A994-B5DF69E316F4</gtr:id><gtr:title>When should antiretroviral therapy be started for HIV-infected infants in resource-limited settings?</gtr:title><gtr:parentPublicationTitle>Future HIV Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3164abe52910f05ccfe8826fc886f6c9"><gtr:id>3164abe52910f05ccfe8826fc886f6c9</gtr:id><gtr:otherNames>Prendergast A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>n5KGhh9afFm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E00697B-65B4-4F6D-931B-7BBFB43400AB</gtr:id><gtr:title>Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children</gtr:title><gtr:parentPublicationTitle>AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49f7ef523fb0f452490b47c3ea62ed37"><gtr:id>49f7ef523fb0f452490b47c3ea62ed37</gtr:id><gtr:otherNames>Dunn D. T.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a3603f5622832.45749999</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C60AD1F-1790-446F-ADB9-EDF97D4D16DA</gtr:id><gtr:title>Transient viral load increases in HIV-infected children in the U.K. and Ireland: what do they mean?</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0adb6e1e21482905a8463debdc02a98e"><gtr:id>0adb6e1e21482905a8463debdc02a98e</gtr:id><gtr:otherNames>Lee KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>jEHjwsnwZdJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14017AE6-425D-4159-A9AD-C82571B349B7</gtr:id><gtr:title>Which strategy for ART in resource-limited settings?</gtr:title><gtr:parentPublicationTitle>The Lancet HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b4c5c5b5c31799afe907f5bcc172f60"><gtr:id>3b4c5c5b5c31799afe907f5bcc172f60</gtr:id><gtr:otherNames>Laurent C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5460f29218d988.74586548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14ADE6E9-B57B-40D8-AFD9-E66BB9EA93D8</gtr:id><gtr:title>Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis.</gtr:title><gtr:parentPublicationTitle>The lancet. HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/183477fd03e755ffd093359907ffb43e"><gtr:id>183477fd03e755ffd093359907ffb43e</gtr:id><gtr:otherNames>Phillips AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2352-3018</gtr:issn><gtr:outcomeId>5460f0899b56a5.05858927</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A9B665B-5C58-4C5C-AE45-B983D536F2A1</gtr:id><gtr:title>The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3815ee07e55fd6613ab25a4413ed8388"><gtr:id>3815ee07e55fd6613ab25a4413ed8388</gtr:id><gtr:otherNames>Ryan M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>Qp3iV4Anf2n</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9976F7B-F701-4F9D-BFA0-E9F4E1596449</gtr:id><gtr:title>Treatment of young children with HIV infection: using evidence to inform policymakers.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe867304a2afe0453c28f658bc7e187c"><gtr:id>fe867304a2afe0453c28f658bc7e187c</gtr:id><gtr:otherNames>Prendergast AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>pm_14873_23_22910874</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F147B52-1E7D-47BC-ADC4-25BA87A333D8</gtr:id><gtr:title>Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7dce5a78a3a3902abda3b00e1cd215ac"><gtr:id>7dce5a78a3a3902abda3b00e1cd215ac</gtr:id><gtr:otherNames>HIV Paediatric Prognostic Markers Collaborative Study</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>FhwGiiwt5eB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A16A3F6-5FD7-4347-9228-948AE85E7F51</gtr:id><gtr:title>Treatment interruption in children with HIV infection.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68a3b528ff9b1f0d0bddbdf896177d53"><gtr:id>68a3b528ff9b1f0d0bddbdf896177d53</gtr:id><gtr:otherNames>Green H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>C6aG6aiCsD7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>598349C4-095F-4E71-B316-720DCA293E93</gtr:id><gtr:title>Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1bd0cf765f643f4aeca480fd4dbde9c"><gtr:id>b1bd0cf765f643f4aeca480fd4dbde9c</gtr:id><gtr:otherNames>Goetghebuer T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>aj89e3Nb4Bj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59D1F569-9DB8-4BAD-8F29-F9D39CB3CE88</gtr:id><gtr:title>When should children with HIV infection be started on antiretroviral therapy?</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cc1c021dd4ad1806a137c175055aab9"><gtr:id>7cc1c021dd4ad1806a137c175055aab9</gtr:id><gtr:otherNames>Welch SB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>VZ9DHawmQve</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B5FF378-5909-45F0-AF95-A2F0F295B1E4</gtr:id><gtr:title>Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.</gtr:title><gtr:parentPublicationTitle>The Lancet. Global health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df45bbde2fa354f91b34a4853de41aac"><gtr:id>df45bbde2fa354f91b34a4853de41aac</gtr:id><gtr:otherNames>Eaton JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2214-109X</gtr:issn><gtr:outcomeId>5460f0501ea115.85997336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21D3C8F4-7311-45E9-B646-FB14782C7A5B</gtr:id><gtr:title>Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f2279647f4209b48e279a9f022a1f4d"><gtr:id>9f2279647f4209b48e279a9f022a1f4d</gtr:id><gtr:otherNames>Oudijk JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_14873_23_22546991</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B45164F9-7970-4926-8F7E-BA48D6F01F10</gtr:id><gtr:title>Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.</gtr:title><gtr:parentPublicationTitle>Archives of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13b769a2fb83ff1e7790ea82df90d227"><gtr:id>13b769a2fb83ff1e7790ea82df90d227</gtr:id><gtr:otherNames>Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-9926</gtr:issn><gtr:outcomeId>KRbUq5W6fTM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9A9B77C-346A-40B5-88BA-260B3EF8C6DE</gtr:id><gtr:title>Early infant diagnosis of HIV infection in low-income and middle-income countries: does one size fit all?</gtr:title><gtr:parentPublicationTitle>The Lancet Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c6149905b45decff9078bd06677f39c"><gtr:id>8c6149905b45decff9078bd06677f39c</gtr:id><gtr:otherNames>Penazzato M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5460ebe3697222.23330340</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2963EF32-DAA9-4E61-ABA9-192E697EE198</gtr:id><gtr:title>Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/328dbfe00b1c693dbd866cc551d138bd"><gtr:id>328dbfe00b1c693dbd866cc551d138bd</gtr:id><gtr:otherNames>Mwenya DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>XKVGSrArkCB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D000EE21-B2B3-453F-8083-ED9E5FB304F7</gtr:id><gtr:title>Vertically acquired HIV diagnosed in adolescence and early adulthood in the United Kingdom and Ireland: findings from national surveillance.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1816521cf70493060b185b80207903df"><gtr:id>1816521cf70493060b185b80207903df</gtr:id><gtr:otherNames>Judd A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>sdoVRrzT5uS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1CEFE2A-6F41-457B-ACD0-C5A6C709BD9A</gtr:id><gtr:title>Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/807907210ceade90d704265bbc5bc924"><gtr:id>807907210ceade90d704265bbc5bc924</gtr:id><gtr:otherNames>Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>eGNh5RQbYzE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F3893D9-EF5B-464F-B4AF-A57E23611AF0</gtr:id><gtr:title>Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f848550dbe891932000645627591af7c"><gtr:id>f848550dbe891932000645627591af7c</gtr:id><gtr:otherNames>Foster C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>UPborWx9Ymg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>591F2201-8C32-4512-A729-8E8F5F408731</gtr:id><gtr:title>Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a85a4081d2554a9d6391e21802e5fdd"><gtr:id>3a85a4081d2554a9d6391e21802e5fdd</gtr:id><gtr:otherNames>Bwakura-Dangarembizi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>545d0b9a559d29.40906247</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C7A7783-61AE-4F99-96A7-1A1C73F26705</gtr:id><gtr:title>Immediate antiretroviral therapy in young HIV-infected children: benefits and risks.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d66b4398b1376bf2dece8528b69a272c"><gtr:id>d66b4398b1376bf2dece8528b69a272c</gtr:id><gtr:otherNames>Collins IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>5460999d76a480.55400419</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A492D73-0B50-4BD0-B4B3-70BBCABD586C</gtr:id><gtr:title>Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1468a3c79a930345b1162a38bc32d1aa"><gtr:id>1468a3c79a930345b1162a38bc32d1aa</gtr:id><gtr:otherNames>Gupta RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>B1zZizubPw1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDB56880-65BC-4E82-A05B-8D40CC66AD4B</gtr:id><gtr:title>Using modeling to inform international guidelines for antiretroviral treatment.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47920c0acbc786b9526f10999fa6b48c"><gtr:id>47920c0acbc786b9526f10999fa6b48c</gtr:id><gtr:otherNames>Hallett TB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5460ef28111de3.27505268</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F60B83B3-0212-4AA2-B6EC-F7F99D0D5D3D</gtr:id><gtr:title>The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e3d78c5672e7bdca46d5ced1d2d76a0"><gtr:id>0e3d78c5672e7bdca46d5ced1d2d76a0</gtr:id><gtr:otherNames>Musiime V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>56e014f80d7391.98020904</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B8E1F80-16B1-4F40-BF22-4E31E5E761AE</gtr:id><gtr:title>Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination &amp;quot;baby pills&amp;quot; in Zambia: a randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f17748497205539169a47b40c5f8f264"><gtr:id>f17748497205539169a47b40c5f8f264</gtr:id><gtr:otherNames>Mulenga V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>kssRjU3VBFM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4A59ED1-332E-41B1-9E48-8A994EF5BFD4</gtr:id><gtr:title>Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a90b45f679d889fd75b95b5af0f57380"><gtr:id>a90b45f679d889fd75b95b5af0f57380</gtr:id><gtr:otherNames>Wittkop L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>5460988c7bbfe9.13548299</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89CD9DDC-7A09-4445-9210-873851D91DCC</gtr:id><gtr:title>A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a85a4081d2554a9d6391e21802e5fdd"><gtr:id>3a85a4081d2554a9d6391e21802e5fdd</gtr:id><gtr:otherNames>Bwakura-Dangarembizi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>545d0c136ec2e6.93812855</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BE1A2E4-D750-43C2-94D9-1301C774D8DF</gtr:id><gtr:title>Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da750d35a95d565812c9c05d32122902"><gtr:id>da750d35a95d565812c9c05d32122902</gtr:id><gtr:otherNames>Bunupuradah T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_14873_23_23135172</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DA56B6F-D906-445C-8B4F-4EA2D12FDC25</gtr:id><gtr:title>Post-licensing safety of fosamprenavir in HIV-infected children in Europe.</gtr:title><gtr:parentPublicationTitle>Pharmacoepidemiology and drug safety</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1816521cf70493060b185b80207903df"><gtr:id>1816521cf70493060b185b80207903df</gtr:id><gtr:otherNames>Judd A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1053-8569</gtr:issn><gtr:outcomeId>5460999d52f3d9.38427577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88220C46-B2C8-4DB6-8E5D-92F400529A08</gtr:id><gtr:title>Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby &amp;amp; Pedimune Junior) are similar to the branded products in healthy adults.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a4062466f813286e6d8eb6ab0ea1581"><gtr:id>1a4062466f813286e6d8eb6ab0ea1581</gtr:id><gtr:otherNames>L'homme RF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>b9UBj18kqQg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDCBFB8D-669B-4BF8-8EA3-0DA717947C12</gtr:id><gtr:title>National policy development for cotrimoxazole prophylaxis in Malawi, Uganda and Zambia: the relationship between Context, Evidence and Links.</gtr:title><gtr:parentPublicationTitle>Health research policy and systems</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a52c65c5ba8da0f240cc372839714e7"><gtr:id>5a52c65c5ba8da0f240cc372839714e7</gtr:id><gtr:otherNames>Hutchinson E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1478-4505</gtr:issn><gtr:outcomeId>pm_14873_23_21679387</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F7B4A77-E0B7-4B38-8EBD-A5B489E0F4C0</gtr:id><gtr:title>Early antiretroviral treatment reduces risk of bacille Calmette-Gu&amp;eacute;rin immune reconstitution adenitis.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/003cfc20380dd203df43f10c0a57786b"><gtr:id>003cfc20380dd203df43f10c0a57786b</gtr:id><gtr:otherNames>Rabie H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>pm_14873_23_21943845</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACE36A6B-595C-4D9C-85B4-963E6410B0F0</gtr:id><gtr:title>Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens</gtr:title><gtr:parentPublicationTitle>AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae3069d954cc2e854e96350ccc51aa70"><gtr:id>ae3069d954cc2e854e96350ccc51aa70</gtr:id><gtr:otherNames>Judd Ali</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5460999e25a878.41403906</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A5FA7E3-56A3-4926-B050-E9A2100D85D8</gtr:id><gtr:title>Recent advances in pharmacovigilance of antiretroviral therapy in HIV-infected and exposed children.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4eddb0cc7499466ab802a8e6d83d23b"><gtr:id>f4eddb0cc7499466ab802a8e6d83d23b</gtr:id><gtr:otherNames>Kenny J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>pm_14873_23_22678488</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C358DFD3-CD88-4DEC-B29D-B00FFA4CE3D8</gtr:id><gtr:title>Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02bed2b4ce3627fb2256368741f8c75b"><gtr:id>02bed2b4ce3627fb2256368741f8c75b</gtr:id><gtr:otherNames>Pursuing Later Treatment Options II (PLATO II) project team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>pm_14873_23_22083070</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BFC4E2C-98D4-491D-BEAF-CA8DACCFD98B</gtr:id><gtr:title>Causes of acute hospitalization in adolescence: burden and spectrum of HIV-related morbidity in a country with an early-onset and severe HIV epidemic: a prospective survey.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93c8a227a88d3a41917c12d45f03d127"><gtr:id>93c8a227a88d3a41917c12d45f03d127</gtr:id><gtr:otherNames>Ferrand RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>hoRgkYMHjX6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3309210A-5B1D-4EF1-89FF-9A4F9F3CD897</gtr:id><gtr:title>Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7845199572fc2439fa34c328b5df0416"><gtr:id>7845199572fc2439fa34c328b5df0416</gtr:id><gtr:otherNames>Riordan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>bTBBjj4T5uf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B127000-02BE-4E18-85E4-339E1AB73D8B</gtr:id><gtr:title>Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0e3de017f65df63ea6e952de4fbef82"><gtr:id>d0e3de017f65df63ea6e952de4fbef82</gtr:id><gtr:otherNames>Bastiaans DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>5458e9e4e1ed84.98540772</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D99712EE-4BE3-4613-B347-5E6EE5637562</gtr:id><gtr:title>Total synthesis of (-)-conophylline and (-)-conophyllidine.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39ff79043df0b8eaa46fc381f4294333"><gtr:id>39ff79043df0b8eaa46fc381f4294333</gtr:id><gtr:otherNames>Han-ya Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>PgdegyQ8W5e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0021BE2-2F71-4194-B265-57E64BBD45FE</gtr:id><gtr:title>The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1f348d127ad0dfafe68772dadfbf883"><gtr:id>d1f348d127ad0dfafe68772dadfbf883</gtr:id><gtr:otherNames>Walker AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>m2FEkayC9xz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3758E8A-E249-425F-898A-3D40C95A2EA0</gtr:id><gtr:title>Utility of clinical parameters to identify HIV infection in infants below ten weeks of age in South Africa: a prospective cohort study.</gtr:title><gtr:parentPublicationTitle>BMC pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1655d7dba3fc393602bc1efb576a056e"><gtr:id>1655d7dba3fc393602bc1efb576a056e</gtr:id><gtr:otherNames>Jaspan HB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1471-2431</gtr:issn><gtr:outcomeId>pm_14873_23_22103994</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE788B3C-575A-4BAE-9CEA-56F91041760C</gtr:id><gtr:title>A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68a3b528ff9b1f0d0bddbdf896177d53"><gtr:id>68a3b528ff9b1f0d0bddbdf896177d53</gtr:id><gtr:otherNames>Green H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>fjFifFwDA8p</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C331C6F3-1A2E-414E-8C2E-787F9E34FE1F</gtr:id><gtr:title>Development of antiretroviral resistance in children with HIV in low- and middle-income countries.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/326e42077b15a71f32cb09425090e555"><gtr:id>326e42077b15a71f32cb09425090e555</gtr:id><gtr:otherNames>Fitzgerald F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_14873_23_23687294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2537E605-F6C7-4ED2-B73A-516CF438B31F</gtr:id><gtr:title>First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1791aadc4cb06cc1063b8502e9be8d52"><gtr:id>1791aadc4cb06cc1063b8502e9be8d52</gtr:id><gtr:otherNames>PENPACT-1 (PENTA 9/PACTG 390) Study Team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>FvjYa9NWaNM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C143AE10-75B0-45C8-A945-A3E7367AC397</gtr:id><gtr:title>Response to combination antiretroviral therapy: variation by age.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d93c3705563a63508cbc695a152a149"><gtr:id>0d93c3705563a63508cbc695a152a149</gtr:id><gtr:otherNames>Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>WneoXHwbetq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70E78107-264A-478F-AAD6-D407C4C5BF9F</gtr:id><gtr:title>Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20b4fd879ac1191d42647203da1ba638"><gtr:id>20b4fd879ac1191d42647203da1ba638</gtr:id><gtr:otherNames>Fillekes Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_14873_23_22739394</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B31AFB0-95D1-4D6F-A604-F597BEC1F376</gtr:id><gtr:title>Increasing antiretroviral drug access for children with HIV infection.</gtr:title><gtr:parentPublicationTitle>Pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bef1c9269d866d04b88a22918f180bf1"><gtr:id>bef1c9269d866d04b88a22918f180bf1</gtr:id><gtr:otherNames>American Academy of Pediatrics Committee on Pediatric AIDS, Section on International Child Health</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0031-4005</gtr:issn><gtr:outcomeId>azA5zjFhFtG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3871617-726D-48C0-92E0-5DCA032C74DA</gtr:id><gtr:title>Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1f348d127ad0dfafe68772dadfbf883"><gtr:id>d1f348d127ad0dfafe68772dadfbf883</gtr:id><gtr:otherNames>Walker AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>iPdeudij4Rh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABF34BC4-766E-4C92-81EB-3AE607C69544</gtr:id><gtr:title>Considerations in the design of randomized controlled trials evaluating the optimal time to initiate antiretroviral therapy in previously untreated HIV-1-infected patients.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a409def97754c3f9b5001e11f39b5b7d"><gtr:id>a409def97754c3f9b5001e11f39b5b7d</gtr:id><gtr:otherNames>Babiker AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>R8DR1R32K37</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC226A11-7C35-4233-8A22-D0C5BB735DFF</gtr:id><gtr:title>Risk of triple-class virological failure in children with HIV: a retrospective cohort study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e54fdd87d76e82626db57fd0593f95e"><gtr:id>5e54fdd87d76e82626db57fd0593f95e</gtr:id><gtr:otherNames>Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>cqeKeqNgT2q</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86E3CD3B-461A-4E3B-9496-C7CA5BCAFDAA</gtr:id><gtr:title>Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bcc217cb69b6a72913b225ba36f677b"><gtr:id>6bcc217cb69b6a72913b225ba36f677b</gtr:id><gtr:otherNames>Haberer JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>hh8H8N4UyNw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11717954-1C2A-4C17-8802-35F08B43E688</gtr:id><gtr:title>Short- and long-term immunological and virological outcome in HIV-infected infants according to the age at antiretroviral treatment initiation.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1bd0cf765f643f4aeca480fd4dbde9c"><gtr:id>b1bd0cf765f643f4aeca480fd4dbde9c</gtr:id><gtr:otherNames>Goetghebuer T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5460999df367a6.01902343</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A8DF94C-DC0B-4CCA-A47C-D8A3D134F6C8</gtr:id><gtr:title>Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f17748497205539169a47b40c5f8f264"><gtr:id>f17748497205539169a47b40c5f8f264</gtr:id><gtr:otherNames>Mulenga V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>Km5sTd9VZqu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD8BAE19-6558-4594-95AE-5E24B0FC9F59</gtr:id><gtr:title>Antiretroviral therapy recommendations for the global community: aspiration versus reality.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/183477fd03e755ffd093359907ffb43e"><gtr:id>183477fd03e755ffd093359907ffb43e</gtr:id><gtr:otherNames>Phillips AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5460efea0daf40.72614167</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65B5CF60-CB41-4B0E-B8D2-9EDD7DBDCEC5</gtr:id><gtr:title>HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd0efa7d2c265a7c0d011f8d7592dd5d"><gtr:id>fd0efa7d2c265a7c0d011f8d7592dd5d</gtr:id><gtr:otherNames>Chakraborty R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>FtaUyuzigMY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3910285-B5BE-4764-8054-7B21FA04210F</gtr:id><gtr:title>Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children.</gtr:title><gtr:parentPublicationTitle>AIDS and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3583e3b7afc8611b8cd7c4a38660e23"><gtr:id>c3583e3b7afc8611b8cd7c4a38660e23</gtr:id><gtr:otherNames>Harrison L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1090-7165</gtr:issn><gtr:outcomeId>pm_14873_23_22584916</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40176668-4E26-4DC5-B557-E14CFD1BA32C</gtr:id><gtr:title>Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1816521cf70493060b185b80207903df"><gtr:id>1816521cf70493060b185b80207903df</gtr:id><gtr:otherNames>Judd A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>Ps7FP6zErcq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CFC3E91-F8A0-4A2D-9055-8EFE7AA1F1A7</gtr:id><gtr:title>Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations.</gtr:title><gtr:parentPublicationTitle>Expert opinion on pharmacotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4513ce17ba45454225dd1302f4983d2"><gtr:id>f4513ce17ba45454225dd1302f4983d2</gtr:id><gtr:otherNames>Krekels EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1465-6566</gtr:issn><gtr:outcomeId>GkRHQfUDp7e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55165A2E-54DC-4482-9D6C-FDC32410C212</gtr:id><gtr:title>Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e5d3e3bd3a7196e35840a52fad1949c"><gtr:id>0e5d3e3bd3a7196e35840a52fad1949c</gtr:id><gtr:otherNames>Chiappini E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5460999dc949b5.43713746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDE80F7E-4CD4-4F1C-B179-A9DA9C744516</gtr:id><gtr:title>Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a4062466f813286e6d8eb6ab0ea1581"><gtr:id>1a4062466f813286e6d8eb6ab0ea1581</gtr:id><gtr:otherNames>L'homme RF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>gVH4BYx799i</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92012C56-C410-455B-959C-1217CC0625DB</gtr:id><gtr:title>Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73432b007f7d670f46513446d5efcbb9"><gtr:id>73432b007f7d670f46513446d5efcbb9</gtr:id><gtr:otherNames>Muro EP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>pm_14873_23_22134145</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93012EA4-B33F-4258-8C46-730A3B3B8728</gtr:id><gtr:title>Incidence of pneumococcal and varicella disease in HIV-infected children and adolescents in the United Kingdom and Ireland, 1996-2011.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38a8b7109cdc0d70aad0062ab59d94c5"><gtr:id>38a8b7109cdc0d70aad0062ab59d94c5</gtr:id><gtr:otherNames>Payne H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>5460999d2e05a4.44221027</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>941BECE4-72D0-4F63-A987-789B42C689CA</gtr:id><gtr:title>Adherence to both cotrimoxazole and placebo is associated with improved survival among HIV-infected Zambian children.</gtr:title><gtr:parentPublicationTitle>AIDS and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1f348d127ad0dfafe68772dadfbf883"><gtr:id>d1f348d127ad0dfafe68772dadfbf883</gtr:id><gtr:otherNames>Walker AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1090-7165</gtr:issn><gtr:outcomeId>bx4FEeJVByJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD2154DE-AE5D-4476-9888-1DBAB7DACF4E</gtr:id><gtr:title>Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services.</gtr:title><gtr:parentPublicationTitle>AIDS patient care and STDs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f848550dbe891932000645627591af7c"><gtr:id>f848550dbe891932000645627591af7c</gtr:id><gtr:otherNames>Foster C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1087-2914</gtr:issn><gtr:outcomeId>W44Vy75Ubb5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C205B7AF-C1A6-4E1B-B3A8-12A3941BA5AD</gtr:id><gtr:title>Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20b4fd879ac1191d42647203da1ba638"><gtr:id>20b4fd879ac1191d42647203da1ba638</gtr:id><gtr:otherNames>Fillekes Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>545d0bc3a38cf0.62745065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>579410EE-8C84-4E7F-AC06-5CE0247E419F</gtr:id><gtr:title>A national sample of individuals who acquired hepatitis C virus infections in childhood or adolescence: risk factors for advanced disease.</gtr:title><gtr:parentPublicationTitle>Journal of pediatric gastroenterology and nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8e11003078dfb39eeb8ebe64762c838"><gtr:id>e8e11003078dfb39eeb8ebe64762c838</gtr:id><gtr:otherNames>Harris HE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0277-2116</gtr:issn><gtr:outcomeId>JsKRKwBzCRn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D039B92-E4C2-43C5-9BB2-634EDB1274BA</gtr:id><gtr:title>Mortality in perinatally HIV-infected young people in England following transition to adult care: an HIV Young Persons Network (HYPNet) audit.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9035611da25498ae77452adf0207b6ce"><gtr:id>9035611da25498ae77452adf0207b6ce</gtr:id><gtr:otherNames>Fish R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>5460999d9d27d6.42046326</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DB00BB4-7AE4-4238-BC98-4901F6ED29CD</gtr:id><gtr:title>Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20b4fd879ac1191d42647203da1ba638"><gtr:id>20b4fd879ac1191d42647203da1ba638</gtr:id><gtr:otherNames>Fillekes Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_14873_23_23864647</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11B2D467-CD72-45B4-9BD4-C02B9BD890F2</gtr:id><gtr:title>Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b95a761fbb6944bf0ea328da723353f"><gtr:id>7b95a761fbb6944bf0ea328da723353f</gtr:id><gtr:otherNames>Menson EN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>iGBvQERjix3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8C1DB42-C3BB-4AF7-A213-AF8B45EFB671</gtr:id><gtr:title>Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/619570981e5c1fd56fbbfd0fa3f49528"><gtr:id>619570981e5c1fd56fbbfd0fa3f49528</gtr:id><gtr:otherNames>Dunn D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>geDjTooBFnj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55C15E70-CD14-4B2B-804D-98317AD14673</gtr:id><gtr:title>Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14356e9699c962c762a4c6e584b266bc"><gtr:id>14356e9699c962c762a4c6e584b266bc</gtr:id><gtr:otherNames>Gibb DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>aagHfa5QxnK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A45B7FBE-1FF2-4BC0-927F-F05B9E7AA031</gtr:id><gtr:title>The role of HIV testing, counselling, and treatment in coping with HIV/AIDS in Uganda: a qualitative analysis.</gtr:title><gtr:parentPublicationTitle>AIDS care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0762bb899ef58b61c34366d087672b9a"><gtr:id>0762bb899ef58b61c34366d087672b9a</gtr:id><gtr:otherNames>Nyanzi-Wakholi B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0954-0121</gtr:issn><gtr:outcomeId>KZAr7xxP3EM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDD8A036-B1C9-4525-A38D-C54AC344E2FA</gtr:id><gtr:title>Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bfd7cf3d8aacf5a4a193b1e91e7ea59"><gtr:id>1bfd7cf3d8aacf5a4a193b1e91e7ea59</gtr:id><gtr:otherNames>Phillips A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5460f2b90a4055.62851408</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E7CA493-7817-4476-BD82-3389C48771A6</gtr:id><gtr:title>Translating evidence into policy in low-income countries: lessons from co-trimoxazole preventive therapy.</gtr:title><gtr:parentPublicationTitle>Bulletin of the World Health Organization</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a52c65c5ba8da0f240cc372839714e7"><gtr:id>5a52c65c5ba8da0f240cc372839714e7</gtr:id><gtr:otherNames>Hutchinson E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0042-9686</gtr:issn><gtr:outcomeId>Mn3b8FnRc2E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D03AB5E3-1E8D-46CB-B944-8B66D5459725</gtr:id><gtr:title>Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0dbecd17f4f7bd82362b29113db110c"><gtr:id>a0dbecd17f4f7bd82362b29113db110c</gtr:id><gtr:otherNames>Cressey TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>gN2VPmn53Ut</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31CB9871-00EC-46A6-98CB-D12CE41B0097</gtr:id><gtr:title>Undiagnosed HIV infection among adolescents seeking primary health care in Zimbabwe.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93c8a227a88d3a41917c12d45f03d127"><gtr:id>93c8a227a88d3a41917c12d45f03d127</gtr:id><gtr:otherNames>Ferrand RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pBbu8TMajBa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5BDC483-AB93-4E86-BFA3-987C178203CF</gtr:id><gtr:title>Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24458c08d0d487d652c1a2bfe83e59bc"><gtr:id>24458c08d0d487d652c1a2bfe83e59bc</gtr:id><gtr:otherNames>Kekitiinwa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>QSk8h7eDrJC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16566103-4237-44DF-ABA3-C51022459034</gtr:id><gtr:title>Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df81b4fe5517636448a88ae331a8bc48"><gtr:id>df81b4fe5517636448a88ae331a8bc48</gtr:id><gtr:otherNames>Cotton MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_14873_23_24209829</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>922C462E-8583-4A5D-825F-833E33007245</gtr:id><gtr:title>Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e3d78c5672e7bdca46d5ced1d2d76a0"><gtr:id>0e3d78c5672e7bdca46d5ced1d2d76a0</gtr:id><gtr:otherNames>Musiime V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>545d017a2137e2.64432453</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8928921F-76FC-4F62-888F-FB9FFAB2CBB7</gtr:id><gtr:title>Lopinavir dosing in HIV-infected children in the United Kingdom and Ireland.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/580ed1e27f7e81405129653e15eed505"><gtr:id>580ed1e27f7e81405129653e15eed505</gtr:id><gtr:otherNames>Donegan K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>pm_14873_23_23076384</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDDA7E66-94F9-48CE-901C-5CD2AD6DE5C5</gtr:id><gtr:title>Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8fd8b516d90b4059e76829a03030dd79"><gtr:id>8fd8b516d90b4059e76829a03030dd79</gtr:id><gtr:otherNames>Kasirye P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>pm_14873_23_22190066</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>157AFA67-4467-48A6-8E09-8118128D66BC</gtr:id><gtr:title>Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.</gtr:title><gtr:parentPublicationTitle>Therapeutic drug monitoring</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a64c90478ef1742b34c46c6cfd8d3a7f"><gtr:id>a64c90478ef1742b34c46c6cfd8d3a7f</gtr:id><gtr:otherNames>Burger D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0163-4356</gtr:issn><gtr:outcomeId>YDVmgfw8ZcN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>347FD4D7-E2B4-4010-B693-AD78A2AC9283</gtr:id><gtr:title>Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation.</gtr:title><gtr:parentPublicationTitle>Pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e49a390a76599fada4937603451e6029"><gtr:id>e49a390a76599fada4937603451e6029</gtr:id><gtr:otherNames>Yin DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0031-4005</gtr:issn><gtr:outcomeId>5458e9c2ce4782.70860172</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD20CACF-0321-4937-B634-EA9F5187C4DF</gtr:id><gtr:title>Children with HIV are not small adults: what is different in pharmacology?</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad756da290788ec7ab09c8d1312b059f"><gtr:id>ad756da290788ec7ab09c8d1312b059f</gtr:id><gtr:otherNames>L'homme R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>mrKz4e3H7rE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F78AEA1-7539-4589-B6D0-5AC7733B0C51</gtr:id><gtr:title>Early antiretroviral therapy and mortality among HIV-infected infants.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25e5c41f65243065ce43751737146d78"><gtr:id>25e5c41f65243065ce43751737146d78</gtr:id><gtr:otherNames>Violari A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>gckVep8PCpi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBCED545-98C5-41AE-97EB-61FB242DD46D</gtr:id><gtr:title>Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46867bd5c665b94d660d6d04c62e31df"><gtr:id>46867bd5c665b94d660d6d04c62e31df</gtr:id><gtr:otherNames>Ellis JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>nWyjWPgotq7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>581FBC3A-CDB8-4E7E-8ABA-A4CD6BAA4016</gtr:id><gtr:title>The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/743184f900cf7f05341330efd5ab8b02"><gtr:id>743184f900cf7f05341330efd5ab8b02</gtr:id><gtr:otherNames>Donegan KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_14873_23_22300840</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF37F813-BFEB-4574-8B6A-AD411B448AE3</gtr:id><gtr:title>Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95e0fa3832bdd90396f651925a145639"><gtr:id>95e0fa3832bdd90396f651925a145639</gtr:id><gtr:otherNames>Burman WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>T41UwYRawYu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E00B97B-9DBB-4BFE-AFB3-058AEDAFFE44</gtr:id><gtr:title>Exploring mechanisms of excess mortality with early fluid resuscitation: insights from the FEAST trial.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86eb93149109bb11bc7f076a9c50c2ab"><gtr:id>86eb93149109bb11bc7f076a9c50c2ab</gtr:id><gtr:otherNames>Maitland K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>pm_14873_23_23496872</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E236E284-6377-4B3D-B86B-3790E9107A57</gtr:id><gtr:title>The needs for HIV treatment and care of children, adolescents, pregnant women and older people in low-income and middle-income countries.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4eddb0cc7499466ab802a8e6d83d23b"><gtr:id>f4eddb0cc7499466ab802a8e6d83d23b</gtr:id><gtr:otherNames>Kenny J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_14873_23_23303433</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A21346DC-1507-4AA5-A67B-530BBC208495</gtr:id><gtr:title>Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68a3b528ff9b1f0d0bddbdf896177d53"><gtr:id>68a3b528ff9b1f0d0bddbdf896177d53</gtr:id><gtr:otherNames>Green H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>CKjd2SNMgMq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4176ED9D-9F90-4FC6-AAC0-94E36FA62ACC</gtr:id><gtr:title>Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-&amp;lt;36 months.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/234e2513ef544c45cf1696b44305e1d5"><gtr:id>234e2513ef544c45cf1696b44305e1d5</gtr:id><gtr:otherNames>Paediatric European Network for Treatment of AIDS (PENTA)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>m8J26G32xPJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA515DA2-51BE-44EC-A0C9-2061DB1FD06A</gtr:id><gtr:title>Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a29ad7b3abd488cc7658fc738478907"><gtr:id>7a29ad7b3abd488cc7658fc738478907</gtr:id><gtr:otherNames>Bergshoeff A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>PU3TfBfxkN4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9371AC7-31A1-480B-8E07-A1EC2DB4AF28</gtr:id><gtr:title>The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c364bb47d84d53cfc830c1a911aa5fdf"><gtr:id>c364bb47d84d53cfc830c1a911aa5fdf</gtr:id><gtr:otherNames>Mbisa JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>tp79AoqehYu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B929C5E4-4F9C-4596-9CFA-FBDC41A8AD51</gtr:id><gtr:title>Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.</gtr:title><gtr:parentPublicationTitle>The Lancet. Global health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12d9c8174126a7d51905d8b071c61ba6"><gtr:id>12d9c8174126a7d51905d8b071c61ba6</gtr:id><gtr:otherNames>Keebler D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2214-109X</gtr:issn><gtr:outcomeId>5460f01a2d7272.99161596</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FA791A3-CF19-4103-8708-BA3BDA68CCC8</gtr:id><gtr:title>Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36bf6d0791aab24f9ae44c8acd439a0b"><gtr:id>36bf6d0791aab24f9ae44c8acd439a0b</gtr:id><gtr:otherNames>Lewis J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_14873_23_22205102</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99D4A0DB-B141-4555-9F8B-AE1C6F92AB22</gtr:id><gtr:title>Perception of risk of vertically acquired HIV infection and acceptability of provider-initiated testing and counseling among adolescents in Zimbabwe.</gtr:title><gtr:parentPublicationTitle>American journal of public health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93c8a227a88d3a41917c12d45f03d127"><gtr:id>93c8a227a88d3a41917c12d45f03d127</gtr:id><gtr:otherNames>Ferrand RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0090-0036</gtr:issn><gtr:outcomeId>pm_14873_23_22021300</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>127AFA3E-C927-402B-B36C-9A154C41BF9E</gtr:id><gtr:title>Determinants of survival without antiretroviral therapy after infancy in HIV-1-infected Zambian children in the CHAP Trial.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1f348d127ad0dfafe68772dadfbf883"><gtr:id>d1f348d127ad0dfafe68772dadfbf883</gtr:id><gtr:otherNames>Walker AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>HDiyfbpGFcE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B054D024-527C-4CA0-A4EF-576CC0459297</gtr:id><gtr:title>Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1816521cf70493060b185b80207903df"><gtr:id>1816521cf70493060b185b80207903df</gtr:id><gtr:otherNames>Judd A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>ggyahZFLr1f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA481E51-6F17-4E8D-ABED-DA035E730313</gtr:id><gtr:title>Response to planned treatment interruptions in HIV infection varies across childhood.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce5a8111285d3bc63e05d5af42ae10be"><gtr:id>ce5a8111285d3bc63e05d5af42ae10be</gtr:id><gtr:otherNames>Paediatric European Network for Treatment of AIDS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>gN8mSxa6VLS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A437F5E-D926-4D56-8DCB-C33DE924D47B</gtr:id><gtr:title>The Lablite project: a cross-sectional mapping survey of decentralized HIV service provision in Malawi, Uganda and Zimbabwe.</gtr:title><gtr:parentPublicationTitle>BMC health services research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b72ee7fa5cffa46951b87bbea236715"><gtr:id>1b72ee7fa5cffa46951b87bbea236715</gtr:id><gtr:otherNames>Chan AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1472-6963</gtr:issn><gtr:outcomeId>5460eb8b188995.65054708</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BC91453-17F2-41BA-B691-0D8199F98417</gtr:id><gtr:title>Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7dce5a78a3a3902abda3b00e1cd215ac"><gtr:id>7dce5a78a3a3902abda3b00e1cd215ac</gtr:id><gtr:otherNames>HIV Paediatric Prognostic Markers Collaborative Study</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>mt9uWyeBbyJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C07E9E0F-6A0D-42DA-B6B0-1E737267FE44</gtr:id><gtr:title>The Methodological Challenges for the Estimation of Quality of Life in Children for Use in Economic Evaluation in Low-Income Countries</gtr:title><gtr:parentPublicationTitle>Value in Health Regional Issues</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13175593ad10e500a71aabc84a681db1"><gtr:id>13175593ad10e500a71aabc84a681db1</gtr:id><gtr:otherNames>Mabugu T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>UkbnaNFTH2K</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BAB5D2D-CAD7-4C17-B830-AE3A3F12896D</gtr:id><gtr:title>Outcomes for human immunodeficiency virus-1-infected infants in the United kingdom and Republic of Ireland in the era of effective antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5d1396d74a918505a05f673b969ab05"><gtr:id>a5d1396d74a918505a05f673b969ab05</gtr:id><gtr:otherNames>Doerholt K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>oY9bEJD132L</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54903431-8545-48F2-BBD7-E4EC36836EF7</gtr:id><gtr:title>The immunological and virological consequences of planned treatment interruptions in children with HIV infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce7d22f3749fc0e74eb321a4edccf869"><gtr:id>ce7d22f3749fc0e74eb321a4edccf869</gtr:id><gtr:otherNames>Klein N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14873_23_24194841</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U122886353</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>